- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02111252
A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Descripción general del estudio
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Tokyo
-
Sumida-ku, Tokyo, Japón
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
3. The participant is a healthy Japanese adult male or female. 4. The participant is aged 20 to 49 years, inclusive, at the time of informed consent.
5. The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m2, inclusive, at the time of eligibility evaluation.
6. If the participant is a female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
Exclusion Criteria:
1. The participant has received any investigational compound within 4 months prior to the initial injection of study vaccine.
2. The participant has been vaccinated with seasonal influenza vaccine within 6 months prior to the initial injection of study vaccine.
3. The participant has a history of influenza infection within 6 months prior to the initial injection of study vaccine 4. The participant is a study site employee, an immediate family member of such an employee, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.
5. The participant has uncontrolled, clinically significant manifestations of neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, endocrine or other disorders, which may impact the ability of the participant to participate or potentially confound the study results.
6. The participant has an oral temperature ≥37.5°C prior to the initial injection of study vaccine on Day 1.
7. The participant has any medically diagnosed or suspected immune deficient condition.
8. The participant has an immune compromising condition or disease, or is currently undergoing a form of treatment or was undergoing a form of treatment that can be expected to influence immune response within 30 days prior to the initial injection of study vaccine. Such treatments include, but is not limited to, systemic or high dose inhaled corticosteroids (>800 μg/day of beclomethasone dipropionate or equivalent; the use of inhaled and nasal steroids that do not exceed this level will be permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.
9. The participant has received antipyretics within 4 hours prior to the initial injection of study vaccine.
10. The participant has a history of Guillain- Barré Syndrome, demyelinating disorders (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis) or convulsions.
11. The participant has a functional or surgical asplenia. 12. The participant has a rash, other dermatologic conditions or tattoos which may interfere with the evaluation of injection site reaction as determined by the Investigator.
13. The participant has a history of, or is infected with the Hepatitis B Virus (HBsAgs), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).
14. The participant has a known hypersensitivity to any component of TAK-850. 15. The participant has a history of severe allergic reactions or anaphylaxis. 16. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the initial injection of study vaccine or is unwilling to agree to abstain from alcohol and drugs throughout the study.
17. The participant has received any blood products (e.g. blood transfusion or immunoglobulin) within 90 days prior to the initial injection of study vaccine.
18. The participant has received a live vaccine within 4 weeks (28 days) or an inactivated vaccine within 2 weeks (14 days) prior to the initial injection of study vaccine.
19. If female, the participant is pregnant or lactating or intending to become pregnant before signing informed consent, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
20. The participant has donated whole blood ?200 mL within 4 weeks (28 days), ≥400 mL within 12 weeks (84 days), ≥800 mL within 52 weeks (364 days), or blood components within 2 weeks (14 days) prior to the initial injection of study vaccine.
21. The participant has abnormal (clinically significant) electrocardiogram (ECG) at the assessment prior to the initial injection of study vaccine.
22. The participant has abnormal laboratory values that suggest a clinically significant underlying disease at the assessment prior to the initial injection of study vaccine, or the participant has the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 3 times the upper limits of normal.
23. In the opinion of the investigator or subinvestigator, the participant is unlikely to comply with protocol requirements or is considered ineligible for any other reason.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: TAK-850 0.5 mL
A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
|
Inyección TAK-850
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Solicited Injection Site and Systemic Adverse Events
Periodo de tiempo: For 22 days
|
Number of participants with injection site and systemic adverse events will be tabulated in its own, and by severity and day of onset.
Described if solicited adverse event term is different from the PT.
|
For 22 days
|
Percentage of Participants With Seroprotection Rate of Hemagglutination Inhibition [HI] Antibody Titer
Periodo de tiempo: Day 22
|
Seroprotection rate is measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
Seroprotection Rate was defined as the percentage of participants with HI antibody titer ≥ 40 for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).
|
Day 22
|
Seroconversion Rate of HI AntibodyTiter
Periodo de tiempo: Day 22
|
Seroconversion rate is measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
Seroconversion Rate was defined as the perccentage of participants with a baseline HI antibody titer of ≥ 10 achieving a minimal 4-fold increase, or baseline HI antibody titer of < 10 achieving an HI antibody titer of ≥ 40 for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).
|
Day 22
|
Geometric Mean Fold Increase in HI Antibody Titer
Periodo de tiempo: Day 22
|
Geometric mean fold increase in HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared to baseline.
|
Day 22
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change From Baseline in Blood Pressure
Periodo de tiempo: Day 1 (Baseline), Day 8, Day 22
|
For continuous variables, summary statistics of measured values and respective changes from baseline will be calculated at each evaluation time point.
In addition, figures illustrating individual changes will be created.
For discrete variables, shift tables (before and after vaccination) will be created.
|
Day 1 (Baseline), Day 8, Day 22
|
Change From Baseline in Safety Electrocardiogram (ECG) Parameters
Periodo de tiempo: Day 1 and Day 22
|
The ECG data will be analyzed into 3 categories, 'normal', 'abnormal but not clinically significant' and 'abnormal clinically significant'.
Using these variables, shift tables (before and after vaccination) will be created by individual participant. .
The definitions for the acronyms are as follows: Within Normal Limits (WNL), Not Clinically Significant (NCS), and Clinically Significant (CS).
|
Day 1 and Day 22
|
Geometric Mean Titer (GMT) of HI Antibody Titer
Periodo de tiempo: Day 22
|
Geometric mean titer (GMT) of HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination
|
Day 22
|
GMT of Single Radial Hemolysis (SRH) Antibody Titer
Periodo de tiempo: Day 22
|
GMT of single radial hemolysis (SRH) antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
|
Day 22
|
Seroprotection Rate of SRH Antibody Titer
Periodo de tiempo: Day 22
|
Seroprotection rate is measured by SRH antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
|
Day 22
|
Seroconversion Rate of SRH Antibody Titer
Periodo de tiempo: Day 22
|
Seroconversion rate as measured by SRH antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination.
|
Day 22
|
Geometric Mean Fold Increase in SRH Antibody Titer
Periodo de tiempo: Day 22
|
Geometric mean fold increase in SRH antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared to baseline.
|
Day 22
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- TAK-850/CPH-001
- U1111-1153-8702 (Identificador de registro: UTN (WHO))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre TAK-850
-
TakedaTerminadoInfección por influenza
-
TakedaTerminadoInfección por influenzaJapón
-
TakedaRetiradoPrevención de la influenzaJapón
-
Al-Azhar UniversityAún no reclutando
-
TakedaTerminado
-
TakedaTerminadoDesorden hiperactivo y deficit de atencionEstados Unidos
-
TakedaTerminadoEnfermedad cardiovascular | Diabetes tipo 2Estados Unidos, Francia, Polonia, Ucrania, Alemania, Hong Kong, Taiwán, Argentina, Israel, México, Bulgaria, Malasia, Rumania, Canadá, Corea, república de, Nueva Zelanda, Perú, Estonia, Filipinas, Federación Rusa, República Checa, Hu... y más
-
Neurocrine BiosciencesTakedaTerminadoEsquizofrenia, Ataxia CerebelosaReino Unido